"Lypressin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.
| Descriptor ID |
D008236
|
| MeSH Number(s) |
D06.472.699.631.692.781.400 D12.644.400.900.400 D12.644.456.925.480 D12.644.548.691.692.781.400 D12.776.631.650.937.400
|
| Concept/Terms |
Lypressin- Lypressin
- 8-Lysine Vasopressin
- 8 Lysine Vasopressin
- Vasopressin, 8-Lysine
- Lysyl Vasopressin
- Vasopressin, Lysyl
- Lys-Vasopressin
- Lys Vasopressin
- Lysine Vasopressin
- Vasopressin, Lysine
|
Below are MeSH descriptors whose meaning is more general than "Lypressin".
Below are MeSH descriptors whose meaning is more specific than "Lypressin".
This graph shows the total number of publications written about "Lypressin" by people in this website by year, and whether "Lypressin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 4 | 4 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lypressin" by people in Profiles.
-
Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2026 Apr; 24(4):1079-1091.
-
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1192-1201.
-
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology. 2024 05 01; 79(5):1048-1064.
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. 2024 04 01; 30(4):347-355.
-
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome. Kidney360. 2023 08 01; 4(8):1030-1038.
-
Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3455-3457.e3.
-
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022 10; 56(8):1284-1293.
-
Predictors of Response to Terlipressin in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 07; 16(7):1174.
-
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017 Jun; 45(11):1390-1402.
-
Terlipressin Improves Renal Function and Reverses Hepatorenal?Syndrome in Patients With Systemic Inflammatory?Response?Syndrome. Clin Gastroenterol Hepatol. 2017 02; 15(2):266-272.e1.